Program
tirbanibulin
Also written as “KX2-391”, “Tirbanibulin ointment 1%” and “KX01 ointment 1%”.
Its studies are mostly in Keratosis, Actinic · Warts · Psoriasis · Prostatic Neoplasms · Dermatitis, Phototoxic, led by 5 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Almirall | 41 open or running | phase 4since May 19, 2022 | Mar 1, 2022 | Jul 2027phase 4 · NCT05387525 |
| Athenex | 30 open or running | phase 2since Feb 22, 2010 | Jan 15, 2008 | none ahead |
| PharmaEssentia | 30 open or running | phase 3since Jan 28, 2022 | Dec 30, 2021 | none ahead |
| Hanmi Pharmaceutical | 10 open or running | phase 2since Jan 2, 2013 | Jan 2, 2013 | none ahead |
| The Skin Center Dermatology Group | 11 open or running | phase 4since Jan 19, 2025 | Jan 19, 2025 | none ahead |
Also a collaborator on its studies: pharmaessentia-japan-k-k.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 15, 2008First study: phase 1 study in LymphomaNew to AthenexAthenex · NCT00658970 · 50 enrolled · United States
- Feb 22, 2010Phase 2 study in Bone-Metastatic, Castration-Resistant Prostate CancerAthenex · NCT01074138 · 31 enrolled · United States
- Jul 18, 2011Phase 1 study in Leukemia, Myeloid, AcuteAthenex · NCT01397799 · 24 enrolled · United States
- Jan 2, 2013Hanmi Pharmaceutical's first study: phase 2 study in Stomach NeoplasmsNew to Hanmi PharmaceuticalHanmi Pharmaceutical · NCT01764087 · 60 enrolled · Korea, Republic of
- Dec 30, 2021PharmaEssentia's first study: phase 1 study in Dermatitis, PhototoxicNew to PharmaEssentiaPharmaEssentia · NCT05245578 · 20 enrolled · Japan
- Jan 28, 2022Phase 3 study in Keratosis, ActinicPharmaEssentia · NCT05231044 · 108 enrolled · Japan
- Mar 1, 2022Almirall's first study: phase 3 study in Keratosis, ActinicNew to AlmirallAlmirall · NCT05279131 · 105 enrolled · United States
- May 19, 2022Phase 4 study in Keratosis, ActinicAlmirall · NCT05387525 · 447 enrolled · France, Germany, Italy and more
- Aug 25, 2022Phase 1 study in PsoriasisPharmaEssentia · NCT05522816 · 28 enrolled
- Feb 14, 2023Phase 4 study in Keratosis, ActinicAlmirall · NCT05741294 · 334 enrolled · Italy, Spain
- Nov 13, 2023Phase 3 study in Keratosis, ActinicAlmirall · NCT06135415 · 280 enrolled · Germany, Italy, Netherlands and more
- Jan 19, 2025The Skin Center Dermatology Group's first study: phase 4 study in Warts HandNew to The Skin Center Dermatology GroupThe Skin Center Dermatology Group · NCT06791525 · 10 planned · United States
Ahead
- Nov 1, 2026Primary completion: phase 4 study in Warts HandThe Skin Center Dermatology Group · NCT06791525
- Jul 2027Primary completion: phase 4 study in Keratosis, ActinicAlmirall · NCT05387525
TargetBeta
“Tyrosine-protein kinase SRC inhibitor”ChEMBL 37, by rule
Other programs on SRC
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| repotrectinibrule | Bristol-Myers Squibb | phase 3 | 9 |
| SRC/YES1 Kinase Inhibitor NXP900rule | nuvectis-pharma-inc | phase 1 | 3 |
Studies
All 12 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06791525Warts Hand · United States | 4 | Recruiting | The Skin Center Dermatology Group | Nov 1, 2026 | 10 |
| NCT06135415Keratosis, Actinic · Germany, Italy, Netherlands and more | 3 | Completed | Almirall | Apr 30, 2025 | 280 |
| NCT05741294Keratosis, Actinic · Italy, Spain | 4 | Completed | Almirall | Jan 19, 2024 | 334 |
| NCT05522816Psoriasis | 1 | Completed | PharmaEssentia | Mar 10, 2021 | 28 |
| NCT05387525Keratosis, Actinic · France, Germany, Italy and more | 4 | Active, not recruiting | Almirall | Jul 2027 | 447 |
| NCT05279131Keratosis, Actinic · United States | 3 | Completed | Almirall | Dec 28, 2022 | 105 |
| NCT05231044Keratosis, Actinic · Japan | 3 | Completed | PharmaEssentia | Nov 20, 2023 | 108 |
| NCT05245578Dermatitis, Phototoxic · Japan | 1 | Completed | PharmaEssentia | Nov 22, 2021 | 20 |
| NCT01764087Stomach Neoplasms · Korea, Republic of | 2 | UNKNOWN | Hanmi Pharmaceutical | Dec 2015 | 60 |
| NCT01397799Leukemia, Myeloid, Acute · United States | 1 | Completed | Athenex | Jul 2014 | 24 |
| NCT01074138Bone-Metastatic, Castration-Resistant Prostate Cancer · United States | 2 | Completed | Athenex | Jun 2012 | 31 |
| NCT00658970Lymphoma · United States | 1 | Completed | Athenex | Mar 2010 | 50 |
How it is read
Names in the registry
- “KX2-391”, 3 entries
- “Tirbanibulin ointment 1%”, 2 entries
- “KX01 ointment 1%”, 2 entries
- “Tirbanibulin”, 1 entry
- “KX01 0.01% (0.1 mg/g)”, 1 entry
Conditions, from the studies’ own filings
- Keratosis, Actinic, 5 studies
- Warts, 1 study
- Psoriasis, 1 study
- Prostatic Neoplasms, 1 study
- Dermatitis, Phototoxic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.